Short Interest in Organogenesis Holdings Inc. (NASDAQ:ORGO) Increases By 29.1%

Organogenesis Holdings Inc. (NASDAQ:ORGO) saw a large increase in short interest in the month of December. As of December 15th, there was short interest totalling 11,000,000 shares, an increase of 29.1% from the November 30th total of 8,520,000 shares. Based on an average daily volume of 690,900 shares, the days-to-cover ratio is currently 15.9 days. Approximately 16.3% of the company’s stock are sold short.

Insiders Place Their Bets

In other Organogenesis news, CEO Gary S. Gillheeney sold 41,052 shares of the business’s stock in a transaction that occurred on Monday, December 9th. The shares were sold at an average price of $3.52, for a total transaction of $144,503.04. Following the completion of the transaction, the chief executive officer now owns 3,359,726 shares in the company, valued at $11,826,235.52. The trade was a 1.21 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Insiders have sold a total of 278,116 shares of company stock worth $991,190 in the last quarter. 36.90% of the stock is owned by company insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in the company. The Manufacturers Life Insurance Company increased its holdings in shares of Organogenesis by 15.4% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 30,984 shares of the company’s stock valued at $87,000 after acquiring an additional 4,130 shares during the period. Mackenzie Financial Corp grew its position in Organogenesis by 46.1% in the 2nd quarter. Mackenzie Financial Corp now owns 24,328 shares of the company’s stock valued at $68,000 after buying an additional 7,678 shares during the last quarter. Pallas Capital Advisors LLC raised its position in Organogenesis by 70.8% during the 3rd quarter. Pallas Capital Advisors LLC now owns 21,823 shares of the company’s stock worth $63,000 after buying an additional 9,048 shares during the last quarter. Massachusetts Financial Services Co. MA lifted its stake in shares of Organogenesis by 3.5% in the 2nd quarter. Massachusetts Financial Services Co. MA now owns 269,741 shares of the company’s stock worth $755,000 after acquiring an additional 9,054 shares during the period. Finally, State Street Corp lifted its stake in shares of Organogenesis by 0.6% in the 3rd quarter. State Street Corp now owns 1,459,767 shares of the company’s stock worth $4,175,000 after acquiring an additional 9,090 shares during the period. Hedge funds and other institutional investors own 49.57% of the company’s stock.

Organogenesis Price Performance

Organogenesis stock opened at $3.16 on Tuesday. The company has a current ratio of 3.09, a quick ratio of 2.74 and a debt-to-equity ratio of 0.21. The company has a fifty day simple moving average of $3.46 and a 200-day simple moving average of $3.04. The stock has a market cap of $397.29 million, a P/E ratio of -52.67 and a beta of 1.73. Organogenesis has a 12-month low of $2.16 and a 12-month high of $4.70.

Organogenesis (NASDAQ:ORGO) last posted its quarterly earnings results on Tuesday, November 12th. The company reported $0.09 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.02) by $0.11. Organogenesis had a negative return on equity of 2.69% and a negative net margin of 1.62%. The company had revenue of $115.18 million for the quarter, compared to analysts’ expectations of $109.59 million. During the same period last year, the firm earned $0.02 earnings per share. Equities analysts expect that Organogenesis will post -0.07 EPS for the current fiscal year.

Organogenesis Company Profile

Organogenesis Holdings Inc, a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage.